A viral insulin-like peptide is a natural competitive antagonist of the human IGF-1 receptor.

IGF-1 Insulin Insulin-like growth factor 1 Peptide synthesis Receptor antagonism Virus-derived peptides

Journal

Molecular metabolism
ISSN: 2212-8778
Titre abrégé: Mol Metab
Pays: Germany
ID NLM: 101605730

Informations de publication

Date de publication:
11 2021
Historique:
received: 11 04 2021
revised: 03 08 2021
accepted: 10 08 2021
pubmed: 18 8 2021
medline: 24 3 2022
entrez: 17 8 2021
Statut: ppublish

Résumé

Natural sources of molecular diversity remain of utmost importance as a reservoir of proteins and peptides with unique biological functions. We recently identified such a family of viral insulin-like peptides (VILPs). We sought to advance the chemical methods in synthesis to explore the structure-function relationship within these VILPs, and the molecular basis for differential biological activities relative to human IGF-1 and insulin. Optimized chemical methods in synthesis were established for a set of VILPs and related analogs. These modified forms included the substitution of select VILP chains with those derived from human insulin and IGF-1. Each peptide was assessed in vitro for agonism and antagonism at the human insulin and the human insulin-like growth factor 1 receptor (IGF-1R). We report here that one of these VILPs, lymphocystis disease virus-1 (LCDV1)-VILP, has the unique property to be a potent and full antagonist of the IGF-1R. We demonstrate the coordinated importance of the B- and C-chains of the VILP in regulating this activity. Moreover, mutation of the glycine following the first cysteine in the B-chain of IGF-1 to serine, in concert with substitution to the connecting peptide of LCDV1-VILP, converted native IGF-1 to a high potency antagonist. The results reveal novel aspects in ligand-receptor interactions at the IGF-1 receptor and identify a set of antagonists of potential medicinal importance.

Identifiants

pubmed: 34400347
pii: S2212-8778(21)00163-0
doi: 10.1016/j.molmet.2021.101316
pmc: PMC8621328
pii:
doi:

Substances chimiques

IGF1R protein, human 0
Neuropeptides 0
insulin-related neuropeptide 0
Receptor, IGF Type 1 EC 2.7.10.1

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

101316

Subventions

Organisme : NIDDK NIH HHS
ID : K01 DK117967
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK036836
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK031036
Pays : United States

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier GmbH.. All rights reserved.

Références

Mutat Res Rev Mutat Res. 2017 Apr - Jun;772:105-122
pubmed: 28528684
Nat Rev Drug Discov. 2016 Jun;15(6):425-39
pubmed: 26988411
Protein Eng. 1996 Nov;9(11):1011-9
pubmed: 8961354
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12429-34
pubmed: 16894147
Endocrinology. 1994 Jul;135(1):472-5
pubmed: 8013387
Nat Rev Drug Discov. 2007 Oct;6(10):821-33
pubmed: 17906644
Horm Metab Res. 1998 Mar;30(3):123-9
pubmed: 9566852
Endocrinology. 2019 Sep 1;160(9):2165-2179
pubmed: 31310273
Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2461-2466
pubmed: 29467286
Biochemistry. 2005 Apr 5;44(13):4984-99
pubmed: 15794637
J Biol Chem. 2014 Aug 22;289(34):23683-92
pubmed: 25002580
Nat Commun. 2019 Oct 8;10(1):4567
pubmed: 31594955
Nat Commun. 2018 Feb 26;9(1):821
pubmed: 29483580
Angew Chem Int Ed Engl. 2008;47(6):1102-6
pubmed: 18161716
Diabetologia. 1991 May;34(5):307-13
pubmed: 1713869
Curr Opin Chem Biol. 2011 Jun;15(3):350-4
pubmed: 21489856
J Biol Chem. 1985 Nov 15;260(26):13989-94
pubmed: 4055768
Mol Metab. 2021 Feb;44:101121
pubmed: 33220491
Cells. 2019 Aug 14;8(8):
pubmed: 31416218
Nat Rev Drug Discov. 2002 Oct;1(10):769-83
pubmed: 12360255
Diabetes. 2000 Jun;49(6):999-1005
pubmed: 10866053
Biochem J. 1996 Apr 1;315 ( Pt 1):271-9
pubmed: 8670118
J Biol Chem. 2009 Sep 4;284(36):24106-14
pubmed: 19578119
Curr Protein Pept Sci. 2005 Apr;6(2):151-69
pubmed: 15853652
Acc Chem Res. 2017 Aug 15;50(8):1855-1865
pubmed: 28771323
J Biol Chem. 1990 Sep 15;265(26):15648-52
pubmed: 2168421
Biochemistry. 2002 Jul 30;41(30):9389-97
pubmed: 12135360
Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8387-92
pubmed: 18550829
Nat Rev Cancer. 2012 Feb 16;12(3):159-69
pubmed: 22337149
Mol Endocrinol. 2015 Nov;29(11):1549-57
pubmed: 26366975
Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15040-4
pubmed: 17855560
Vitam Horm. 2009;80:1-31
pubmed: 19251032
Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4435-9
pubmed: 12684539
J Pept Sci. 2016 May;22(5):260-70
pubmed: 26910514
J Biol Chem. 2013 Jul 5;288(27):19593-603
pubmed: 23696648
Science. 1990 Jul 27;249(4967):386-90
pubmed: 1696028

Auteurs

Fa Zhang (F)

Department of Chemistry, Indiana University, Bloomington, IN, 47405, USA.

Emrah Altindis (E)

Boston College Biology Department, Chestnut Hill, MA, 02467, USA.

C Ronald Kahn (CR)

Joslin Diabetes Center, Harvard Medical School, Boston, MA, 02215, USA.

Richard D DiMarchi (RD)

Department of Chemistry, Indiana University, Bloomington, IN, 47405, USA. Electronic address: RDiMarch@indiana.edu.

Vasily Gelfanov (V)

Novo Nordisk Research Center, 5225 Exploration Drive, Indianapolis, IN, 46241, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH